Compare FRBT & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBT | AMPH |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.8M | 885.4M |
| IPO Year | 2026 | 2005 |
| Metric | FRBT | AMPH |
|---|---|---|
| Price | $19.08 | $20.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.38 |
| AVG Volume (30 Days) | 112.5K | ★ 382.8K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | N/A | $4.64 |
| P/E Ratio | ★ N/A | $144.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.72 | $16.65 |
| 52 Week High | $22.00 | $31.26 |
| Indicator | FRBT | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 57.22 |
| Support Level | $18.29 | $18.12 |
| Resistance Level | $21.22 | $20.77 |
| Average True Range (ATR) | 1.45 | 0.64 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 15.63 | 94.71 |
Forbright Inc is a bank holding company. Along with its subsidiaries, it operates as a state chartered non-member bank, which serves the needs of individuals, small and medium sized businesses, and professional concerns. Its services include deposit and retail banking through a digital deposit platform, as well as financing and lending products such as lender finance loans, fund finance loans, healthcare finance loans, real estate loans, working capital facilities, warehouse lines of credit, and term loans.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.